Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Elan dealt a blow with Biogen ruling
- Elan, the Irish domiciled pharmaceuticals company, suffered a sharp setback in its recapitalisation plans when a US judge ruledon Thursday that a planned $1.5bn deal with Johnson & Johnson violated the terms of an existing partnership with Biogen Idec.Deborah Batts, a Manhattan federal court judge, ruled that Elan had...
- External links 2009-09-03
- Whatever Tysabri Outcome, Biogen Idec Should Survive
- Biogen Idec's key multiple sclerosis drug is in the news again, as the European Medicines Agency EMEA has started a safety review of Tysabri, citing more confirmed cases of a rare -- but potentially fatal -- viral infection of the brain, called progressive multifocal leukoencephalopathy PML, previously linked to the...
- Blog posts 2009-10-26
- Biogen-Idec's Tysabri Problems May Be Fault of European Doctors
- As mentioned in my last BNET Pharma posting, Biogen Idec's key multiple sclerosis drug Tysabri had been linked to 23 worldwide cases of a potentially deadly brain infection called progressive multifocal leukoencephalopathy, or PML -- with most confirmed cases centered in Europe, in particular Germany. Could there be a link...
- Blog posts 2009-10-27
Additional Resources
- Reviving Tysabri
- Worries about a potentially deadly side effect have long impeded sales of the multiple sclerosis drug Tysabri, made by Elan. But now the medicine's inventor says he has created a diagnostic test that might reveal those patients who are less at risk of the side effect. That could increase the...
- News items 2009-10-27
- EMEA links 24th PML case to Tysabri
- European regulators offer yet another update on Tysabri-linked cases of progressive multifocal leukoencephalopathy: The grand total is now 24, up from 23 last week and just 13 some six weeks ago. Of those 24 patients, four died. The numbers are coming thick and fast now because the European Union is...
- News items 2009-10-30
- Biogen Idec and Elan Announce Voluntary Suspension of TYSABRI-R-
- CAMBRIDGE, Mass. and DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today a voluntary suspension in the marketing of TYSABRIR natalizumab, a treatment for multiple sclerosis MS. The companies are suspending supply of TYSABRI from commercial distribution and physicians should suspend dosing of TYSABRI...
- Research articles 2005-02-28
- Elan and Biogen Idec Announce TYSABRI® Safety Evaluation Findings in Crohn's Disease and Rheumatoid Arthritis Patients; TYSABRI Safety Evaluation Complete; No New Confirmed Cases of PML
- DUBLIN, Ireland & CAMBRIDGE, Mass. -- Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that findings from their safety evaluation of TYSABRIR natalizumab in patients with Crohn's disease CD and rheumatoid arthritis RA resulted in no new confirmed cases of progressive multifocal leukoencephalopathy PML. The companies...
- Research articles 2005-10-17
- Biogen Idec and Elan Announce Availability of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis
- CAMBRIDGE, Mass. and DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the commercial availability of TYSABRIR natalizumab for the treatment of relapsing forms of multiple sclerosis MS in the U.S. As previously announced, the U.S. Food and Drug Administration FDA approved the supplemental...
- Research articles 2006-07-24
- Biogen Idec and Elan Announce Head-to-Head Study Comparing Safety and Efficacy of TYSABRI-R- to Rebif-R-
- ZUG, Switzerland -- Biogen Idec and Elan announced today that they are initiating a head-to-head study comparing the safety and efficacy of TYSABRIR natalizumab to RebifR (Interferon beta-1a)a. STARS Study of TYSABRI Against Rebif in relapsing multiple Sclerosis, is a randomized, assessor-blinded, parallel group study that will enroll more than...
- Research articles 2004-12-21
- FDA Approves the Reintroduction of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis
- CAMBRIDGE, Mass. & DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the approval of a supplemental Biologics License Application sBLA by the U.S. Food and Drug Administration FDA for the reintroduction of TYSABRIR natalizumab as a monotherapy treatment for relapsing forms of multiple...
- Research articles 2006-06-05
- Elan and Biogen Idec Provide an Update on TYSABRI®
- DUBLIN, Ireland & CAMBRIDGE, Mass. -- Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that in the coming weeks they expect the safety evaluation of TYSABRIR natalizumab in Crohn's disease and rheumatoid arthritis will be completed, and that they will submit a supplemental Biologics License Application...
- Research articles 2005-09-20
- Biogen Idec and Elan Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for TYSABRI(R) in Multiple Sclerosis.
- CAMBRIDGE, Mass. and DUBLIN, Ireland, Nov 17, 2005 CCNMatthews via COMTEX -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that the supplemental Biologics License Application sBLA for TYSABRIR natalizumab fo CAMBRIDGE, Mass. and DUBLIN, Ireland, Nov 17, 2005 (CCNMatthews via ...
- Research articles 2005-11-17
- MS Society Welcomes Tysabri 'Yes'.
- LONDON, July 3 /PRNewswire/ -- THE MS Society has welcomed the National Institute for Health and Clinical Excellence's NICE decision to recommend the use of Tysabri natalizumab to treat people with highly active relapsing remitting multiple s LONDON, July 3 /PRNewswire/ --...
- Research articles 2007-07-02
- FDA Grants Accelerated Approval of TYSABRI, Formerly ANTEGREN, For the Treatment of Multiple Sclerosis.
- CAMBRIDGE, Mass. and SAN DIEGO, Calif. and DUBLIN, Ireland, Nov 23, 2004 CCNMatthews via COMTEX -- Approval of TYSABRI Marks A Major Advancement in the Treatment of MS Phase III Trials at One Year Demonstrate New Level of Efficacy - 66% Reduction i CAMBRIDGE, Mass. and...
- Research articles 2004-11-24
- Biogen Idec and Elan Announce TYSABRI(R) Safety Evaluation Update.
- CAMBRIDGE, Mass. and DUBLIN, Ireland, Aug 9, 2005 CCNMatthews via COMTEX -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that findings from their safety evaluation of TYSABRIR natalizumab in patients with m CAMBRIDGE, Mass. and DUBLIN, Ireland, Aug 9,...
- Research articles 2005-08-09
- Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis.
- CAMBRIDGE, Mass. and DUBLIN, Ireland, Mar 29, 2006 CCNMatthews via COMTEX -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc. (NYSE: ELN) announced today that they have enrolled and dosed the first patients in the TYSABRIR natalizumab mono CAMBRIDGE, Mass. and DUBLIN, Ireland, Mar 29, 2006...
- Research articles 2006-03-29
- TYSABRI® Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in MS
- CAMBRIDGE, Mass. and DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc. (NYSE: ELN) announced today that the Food and Drug Administration FDA informed the companies that they have removed the hold on clinical trial dosing of TYSABRIR natalizumab in multiple sclerosis MS in the U.S. The companies...
- Research articles 2006-02-15
- Tysabri Concerns Continue to Weigh on Biogen, Elan
- EP Vantage submits: Despite reporting strong quarterly revenues and earnings ahead of Wall Street estimates, shares in Biogen Idec BIIB fell 7% Tuesday and continued to fall in yesterday, down even further to a two-year low of $40.72. With shares in one of Biogen Idec’s key partners, Elan ELN,...
- External links 2008-10-23
- Elan and Biogen report positive results for Tysabri and Barrier Therapeutics announces phase 3 results for Hyphanox.
- M2 PRESSWIRE-30 June 2005-US Financial Network: Elan and Biogen report positive results for Tysabri and Barrier Therapeutics announces phase 3 results for HyphanoxC1994-2005 M2 COMMUNICATIONS LTD RDATE:30062005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC:...
- Research articles 2005-06-30
- Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial and ViroPharma Announces Positive Phase 2 Results.
- M2 PRESSWIRE-30 March 2006-US Financial Network: Biogen Idec and Elan Announce Re-Initiation of TYSABRIR Clinical Trial and ViroPharma Announces Positive Phase 2 ResultsC1994-2006 M2 COMMUNICATIONS LTD RDATE:30032006 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC:...
- Research articles 2006-03-30
- << Previous
- page 1 of 1
- Next >>
